Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters

Bibliography

• FXMahon, FBelloc, VLagarde, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101(6):2368–73
   PubMed Web of Science ®Google Scholar
• FJSharom. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9(1):105–27
   PubMed Web of Science ®Google Scholar
• TSaji, RKikuchi, HKusuhara, et al. Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1 alpha/beta. J Pharmacol Exp Ther 2008;324(2):784–90
   PubMed Web of Science ®Google Scholar
• JMMaher, ALSlitt, TNCallaghan, et al. Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem Pharmacol 2006;72(4):512–22
   PubMed Web of Science ®Google Scholar
• RKikuchi, HKusuhara, NHattori, et al. Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1alpha/beta and DNA methylation. Mol Pharmacol 2006;70(3):887–96
   PubMed Web of Science ®Google Scholar
• LJin, RKikuchi, TSaji, et al. Regulation of tissue-specific expression of renal organic anion transporters by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. J Pharmacol Exp Ther 2012;340(3):648–55
   PubMed Web of Science ®Google Scholar
• RKikuchi, HKusuhara, NHattori, et al. Regulation of tissue-specific expression of the human and mouse urate transporter 1 gene by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. Mol Pharmacol 2007;72(6):1619–25
   PubMed Web of Science ®Google Scholar
• KKlein, CJungst, JMwinyi, et al. The human organic anion transporter genes OAT5 and OAT7 are transactivated by hepatocyte nuclear factor-1alpha (HNF-1alpha). Mol Pharmacol 2010;78(6):1079–87
   PubMed Web of Science ®Google Scholar
• KPopowski, JJEloranta, MSaborowski, et al. The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4 alpha and suppressed by bile acids. Mol Pharmacol 2005;67(5):1629–38
   PubMed Web of Science ®Google Scholar
• NAWolff, KThies, NKuhnke, et al. Protein kinase C activation downregulates human organic anion transporter 1-mediated transport through carrier internalization. J Am Soc Nephrol 2003;14(8):1959–68
   PubMed Web of Science ®Google Scholar
• QZhang, MHong, PDuan, et al. Organic anion transporter OAT1 undergoes constitutive and protein kinase C-regulated trafficking through a dynamin- and clathrin-dependent pathway. J Biol Chem 2008;283(47):32570–9
   PubMed Web of Science ®Google Scholar
• MTakeda, TSekine, HEndou. Regulation by protein kinase C of organic anion transport driven by rat organic anion transporter 3 (rOAT3). Life Sci 2000;67(9):1087–93
   PubMedGoogle Scholar
• JOKwak, HWKim, KJOh, et al. Co-localization and interaction of organic anion transporter 1 with caveolin-2 in rat kidney. Exp Mol Med 2005;37(3):204–12
   PubMed Web of Science ®Google Scholar
• KAoki, NSaso, SKato, et al. Nitric oxide and peroxynitrite regulate transporter transcription in rat liver slices. Biol Pharm Bull 2008;31(10):1882–7
   PubMed Web of Science ®Google Scholar
• SZhang, KSLovejoy, JEShima, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006;66(17):8847–57
   PubMed Web of Science ®Google Scholar
• AYonezawa, SMasuda, SYokoo, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319(2):879–86
   PubMed Web of Science ®Google Scholar
• VShnitsar, REckardt, SGupta, et al. Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res 2009;69(4):1494–501
   PubMed Web of Science ®Google Scholar
• MSaborowski, GAKullak-Ublick, JJEloranta. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. J Pharmacol Exp Ther 2006;317(2):778–85
   PubMed Web of Science ®Google Scholar
• YShu, CLBello, LMMangravite, et al. Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J Pharmacol Exp Ther 2001;299(1):392–8
   PubMed Web of Science ®Google Scholar
• GCiarimboli, KStruwe, PArndt, et al. Regulation of the human organic cation transporter hOCT1. J Cell Physiol 2004;201(3):420–8
   PubMed Web of Science ®Google Scholar
• TMehrens, SLelleck, ICetinkaya, et al. The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependent phosphorylation. J Am Soc Nephrol 2000;11(7):1216–24
   PubMed Web of Science ®Google Scholar
• GCiarimboli, HKoepsell, MIordanova, et al. Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol 2005;16(6):1562–70
   PubMed Web of Science ®Google Scholar
• ICetinkaya, GCiarimboli, GYalcinkaya, et al. Regulation of human organic cation transporter hOCT2 by PKA, PI3K, and calmodulin-dependent kinases. Am J Physiol Renal Physiol 2003;284(2):F293–302
   Google Scholar
• FMartel, EKeating, CCalhau, et al. Regulation of human extraneuronal monoamine transporter (hEMT) expressed in HEK-293 cells by intracellular second messenger systems. Naunyn Schmiedebergs Arch Pharmacol 2001;364(6):487–95
   PubMed Web of Science ®Google Scholar
• ESchlatter, VMonnich, ICetinkaya, et al. The organic cation transporters rOCT1 and hOCT2 are inhibited by cGMP. J Membr Biol 2002;189(3):237–44
   PubMed Web of Science ®Google Scholar
• RLOostendorp, Evan de Steeg, CMvan der Kruijssen, et al. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos 2009;37(4):917–23
   PubMed Web of Science ®Google Scholar
• NFSmith, MRAcharya, NDesai, et al. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005;4(8):815–18
   PubMed Web of Science ®Google Scholar
• TAbe, MUnno, TOnogawa, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001;120(7):1689–99
   PubMed Web of Science ®Google Scholar
• TMikkaichi, TSuzuki, TOnogawa, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 2004;101(10):3569–74
   PubMed Web of Science ®Google Scholar
• DAKatz, RCarr, DRGrimm, et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther 2006;79(3):186–96
   PubMed Web of Science ®Google Scholar
• YMiki, TSuzuki, KKitada, et al. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 2006;66(1):535–42
   PubMed Web of Science ®Google Scholar
• DJung, GAKullak-Ublick. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 2003;37(3):622–31
   PubMed Web of Science ®Google Scholar
• TFurihata, TSatoh, NYamamoto, et al. Hepatocyte nuclear factor 1 alpha is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers. Pharm Res 2007;24(12):2327–32
   PubMed Web of Science ®Google Scholar
• MLe Vee, VLecureur, AMoreau, et al. Differential regulation of drug transporter expression by hepatocyte growth factor in primary human hepatocytes. Drug Metab Dispos 2009;37(11):2228–35
   PubMed Web of Science ®Google Scholar
• MLe Vee, EJouan, AMoreau, OFardel. Regulation of drug transporter mRNA expression by interferon-gamma in primary human hepatocytes. Fundam Clin Pharmacol 2011;25(1):99–103
   PubMed Web of Science ®Google Scholar
• MLe Vee, PGripon, BStieger, OFardel. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Drug Metab Dispos 2008;36(2):217–22
   PubMed Web of Science ®Google Scholar
• SRVavricka, DJung, MFried, et al. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol 2004;40(2):212–18
   PubMed Web of Science ®Google Scholar
• JHChoi, JWMurray, AWWolkoff. PDZK1 binding and serine phosphorylation regulate subcellular trafficking of organic anion transport protein 1a1. Am J Physiol Gastrointest Liver Physiol 2011;300(3):G384–93
   Google Scholar
• KKock, AKoenen, BGiese, et al. Rapid modulation of the organic anion transporting polypeptide 2B1 (OATP2B1, SLCO2B1) function by protein kinase C-mediated internalization. J Biol Chem 2010;285(15):11336–47
   PubMed Web of Science ®Google Scholar
• MHuang, YWang, SBCogut, et al. Inhibition of nucleoside transport by protein kinase inhibitors. J Pharmacol Exp Ther 2003;304(2):753–60
   PubMed Web of Science ®Google Scholar
• AVLeisewitz, EIZimmerman, SZJones, et al. Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine. Nucleosides Nucleotides Nucleic Acids 2008;27(6):779–86
   PubMed Web of Science ®Google Scholar
• ELWoodahl, JWang, SHeimfeld, et al. Imatinib inhibition of fludarabine uptake in T-lymphocytes. Cancer Chemother Pharmacol 2008;62(4):735–9
   PubMed Web of Science ®Google Scholar
• JSNaud, KGhani, POde Campos-Lima, MCaruso. Nilotinib and imatinib inhibit cytarabine cellular uptake: implications for combination therapy. Leuk Res 2012;36(10):1311–14
   PubMed Web of Science ®Google Scholar
• SHu, HNiu, HInaba, et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 2011;103(11):893–905
   PubMed Web of Science ®Google Scholar
• VLDamaraju, MKuzma, DMowles, et al. Interactions of Multitargeted Kinase Inhibitors and Nucleoside Drugs: Achilles Heel of Combination Therapy? Mol Cancer Ther 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• MMGottesman, TFojo, SEBates. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2(1):48–58
   PubMed Web of Science ®Google Scholar
• HBronger, JKonig, KKopplow, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 2005;65(24):11419–28
   PubMed Web of Science ®Google Scholar
• RLiedauer, MSvoboda, KWlcek, et al. Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts. Oncol Rep 2009;22(6):1485–92
   PubMed Web of Science ®Google Scholar
• JKonig, YCui, ATNies, DKeppler. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278(1):G156–64
   PubMed Web of Science ®Google Scholar
• HYamaguchi, MOkada, SAkitaya, et al. Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res 2006;47(6):1196–202
   PubMed Web of Science ®Google Scholar
• ASeithel, SEberl, KSinger, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007;35(5):779–86
   PubMed Web of Science ®Google Scholar
• MMuto, TOnogawa, TSuzuki, et al. Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci 2007;98(10):1570–6
   PubMed Web of Science ®Google Scholar
• NRMonks, SLiu, YXu, et al. Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells. Mol Cancer Ther 2007;6(2):587–98
   PubMed Web of Science ®Google Scholar
• MNagai, TFurihata, SMatsumoto, et al. Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochem Biophys Res Commun 2012;418(4):818–23
   PubMed Web of Science ®Google Scholar
• NThakkar, KKim, ERJang, et al. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm 2013;10(1):406–16
   PubMedGoogle Scholar
• WLee, ABelkhiri, ACLockhart, et al. Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 2008;68(24):10315–23
   PubMed Web of Science ®Google Scholar
• KGGotink, HJBroxterman, MLabots, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 2011;17:7337–46
   PubMed Web of Science ®Google Scholar
• JKindla, TTRau, RJung, et al. Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue. Cancer Biol Ther 2011;11(6):584–91
   PubMed Web of Science ®Google Scholar
• KWlcek, MSvoboda, TThalhammer, et al. Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol Ther 2008;7(9):1450–5
   PubMed Web of Science ®Google Scholar
• TNozawa, MSuzuki, KTakahashi, et al. Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. J Pharmacol Exp Ther 2004;311(3):1032–7
   PubMed Web of Science ®Google Scholar
• TNozawa, MSuzuki, HYabuuchi, et al. Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. Pharm Res 2005;22(10):1634–41
   PubMed Web of Science ®Google Scholar
• YCui, JKonig, ATNies, et al. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab Invest 2003;83(4):527–38
   PubMed Web of Science ®Google Scholar
• MNarita, EHatano, SArizono, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009;44(7):793–8
   PubMed Web of Science ®Google Scholar
• AMCalcagno, JALudwig, JMFostel, et al. Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol Pharm 2006;3(1):87–93
   PubMedGoogle Scholar
• SGong, XLu, YXu, et al. Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp Hematol 2002;30(10):1162–9
   PubMed Web of Science ®Google Scholar
• TPark, SGYi, YKShin, SLee. Combining multiple microarrays in the presence of controlling variables. Bioinformatics 2006;22(14):1682–9
   PubMed Web of Science ®Google Scholar
• MHeise, ALautem, JKnapstein, et al. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 2012;12:109
   PubMed Web of Science ®Google Scholar
• JThomas, LWang, REClark, MPirmohamed. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104(12):3739–45
   PubMed Web of Science ®Google Scholar
• ARAsif, JSteffgen, MMetten, et al. Presence of organic anion transporters 3 (OAT3) and 4 (OAT4) in human adrenocortical cells. Pflugers Arch 2005;450(2):88–95
   PubMed Web of Science ®Google Scholar
• VRHolla, MGBacklund, PYang, et al. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila) 2008;1(2):93–9
   PubMed Web of Science ®Google Scholar
• FZhou, ACLee, KKrafczyk, et al. Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. Br J Pharmacol 2011;162(6):1380–8
   PubMed Web of Science ®Google Scholar
• JZheng, TChan, FSCheung, et al. PDZK1 and NHERF1 regulate the function of human organic anion transporting polypeptide 1A2 (OATP1A2) by modulating its subcellular trafficking and stability. PLoS One 2014;9(4):e94712
   Google Scholar
• RANorman, DToader, ADFerguson. Structural approaches to obtain kinase selectivity. Trends Pharmacol Sci 2012;33(5):273–8
   PubMed Web of Science ®Google Scholar
• CALipinski, FLombardo, BWDominy, PJFeeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3–26
   PubMed Web of Science ®Google Scholar
• GLEngel, NAFarid, MMFaul, et al. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm 2000;198(2):239–47
   PubMedGoogle Scholar
• Ple Coutre, KAKreuzer, SPursche, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004;53(4):313–23
   PubMed Web of Science ®Google Scholar
• DLWhite, VASaunders, PDang, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108(2):697–704
   PubMed Web of Science ®Google Scholar
• LWang, AGiannoudis, SLane, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83(2):258–64
   PubMed Web of Science ®Google Scholar
• SHu, RMFranke, KKFilipski, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008;14(10):3141–8
   PubMed Web of Science ®Google Scholar
• SHu, ZChen, RFranke, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15(19):6062–9
   PubMed Web of Science ®Google Scholar
• KEechoute, RMFranke, WJLoos, et al. Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther 2011;89(6):816–20
   PubMed Web of Science ®Google Scholar
• EIZimmerman, SHu, JLRoberts, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 2013;19(6):1458–66
   PubMed Web of Science ®Google Scholar
• DHKim, LSriharsha, WXu, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009;15(14):4750–8
   PubMed Web of Science ®Google Scholar
• TMinematsu, KMGiacomini. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 2011;10(3):531–9
   PubMed Web of Science ®Google Scholar
• MGaletti, RRAlfieri, ACavazzoni, et al. Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. Biochem Pharmacol 2010;80(2):179–87
   PubMed Web of Science ®Google Scholar
• MAElmeliegy, AMCarcaboso, MTagen, et al. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 2011;17(1):89–99
   PubMed Web of Science ®Google Scholar
• KKFilipski, WJLoos, JVerweij, ASparreboom. Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 2008;14(12):3875–80
   PubMed Web of Science ®Google Scholar
• MJGnoth, SSandmann, KEngel, MRadtke. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab Dispos 2010;38(8):1341–6
   PubMed Web of Science ®Google Scholar
• AJde Graan, CSLancaster, AObaidat, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012;18(16):4433–40
   PubMed Web of Science ®Google Scholar
• AGiannoudis, ADavies, CMLucas, et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112(8):3348–54
   PubMed Web of Science ®Google Scholar
• DKHiwase, VSaunders, DHewett, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008;14(12):3881–8
   PubMed Web of Science ®Google Scholar
• JWPolli, JEHumphreys, KAHarmon, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino }methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008;36(4):695–701
   PubMed Web of Science ®Google Scholar
• ADavies, NEJordanides, AGiannoudis, et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009;23(11):1999–2006
   PubMed Web of Science ®Google Scholar
• MBrennan, JAWilliams, YChen, et al. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol 2012;68(5):645–55
   PubMed Web of Science ®Google Scholar
• CFXu, BHReck, ZXue, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphism. Br J Cancer 2010;102(9):1371–7
   PubMed Web of Science ®Google Scholar
• SLeuthold, BHagenbuch, NMohebbi, et al. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol 2009;296(3):C570–82
   PubMed Web of Science ®Google Scholar
• GDi Giusto, NAnzai, HEndou, AMTorres. Elimination of organic anions in response to an early stage of renal ischemia-reperfusion in the rat: role of basolateral plasma membrane transporters and cortical renal blood flow. Pharmacology 2008;81(2):127–36
   PubMed Web of Science ®Google Scholar
• MAHollingsworth, BJSwanson. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4(1):45–60
   PubMed Web of Science ®Google Scholar
• FMarcucci, ACorti. How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs. Adv Drug Deliv Rev 2012;64(1):53–68
   PubMed Web of Science ®Google Scholar
• FMarcucci, ACorti. Improving drug penetration to curb tumor drug resistance. Drug Discov Today 2012;17(19-20):1139–46
   PubMed Web of Science ®Google Scholar
• MRoth, AObaidat, BHagenbuch. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 2012;165(5):1260–87
   PubMed Web of Science ®Google Scholar
• HGlaeser, DGBailey, GKDresser, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362–70
   PubMed Web of Science ®Google Scholar
• HKoepsell, KLips, CVolk. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24(7):1227–51
   PubMed Web of Science ®Google Scholar
• ITamai, JNezu, HUchino, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000;273(1):251–60
   PubMed Web of Science ®Google Scholar
• BMJohnson, WNCharman, CJPorter. The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil. J Pharm Pharmacol 2001;53(12):1611–19
   PubMed Web of Science ®Google Scholar
• Kvan de Wetering, ABurkon, WFeddema, et al. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 2009;75(4):876–85
   PubMed Web of Science ®Google Scholar
• REvers, GJZaman, Lvan Deemter, et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996;97(5):1211–18
   PubMed Web of Science ®Google Scholar
• AInokuchi, EHinoshita, YIwamoto, et al. Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter. J Biol Chem 2001;276(50):46822–9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.solvobiotech.com/barriers/intestinal-barrier
   Google Scholar
• RBorchardt, EKerns, MHageman, et al. Optimizing the “drug-like” properties of leads in drug discovery. Springer; New Yprk: 2006
   Google Scholar
• RJHoneywell, SHitzerd, CFatmawati, et al. Uptake and subcellular distribution of tyrosine kinase inhibitors. Manuscript in preparation
   Google Scholar